Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Total Current Liabilities
All obligations due within one year.
Abeona Therapeutics Inc.NASDAQ: ABEO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 72.6% from a year ago
Total current liabilities stood at $31.05M at the end of Q1 FY2026, up 72.6% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.
Context
- Total current liabilities amounted to 15.6% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +72.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 29.57M USD
- Year-over-year change
- +78.3%
- 4-year CAGR
- +15.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.57M | +78.3% |
| FY2024 | 2024-12-31 | 16.59M | +23.6% |
| FY2023 | 2023-12-31 | 13.42M | +72.5% |
| FY2022 | 2022-12-31 | 7.78M | -53.2% |
| FY2021 | 2021-12-31 | 16.62M | — |
Total Current Liabilities vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's Mar 2026 total current liabilities of $31.05M is the 5th highest of the 10 companies compared; the peer median is $17.45M.
- Its year-over-year change of +72.6% is the highest of 10, against a peer median of -24.9%.
- Total current liabilities amounts to 15.6% of total assets for ABEO, versus a peer median of 14.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $59.74M | -31.1% | +1.6% | 31.0% | |
| Mar 2026 | $35M | -24.9% | +44.1% | 14.9% | |
| Mar 2026 | $34.37M | -30.4% | -34.1% | 14.0% | |
| Mar 2026 | $31.05M | +72.6% | +56.1% | 15.6% | |
| Mar 2026 | $17.45M | -56.6% | -28.5% | 8.0% | |
| Mar 2026 | $16.78M | +18.6% | -14.0% | 12.4% | |
| Mar 2026 | $16.19M | -19.2% | -2.1% | 14.6% | |
| Mar 2026 | $13.46M | +46.5% | +41.5% | 9.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -1.1% | 4.9% |
| Peer median (excluding ABEO) | $17.45M | -24.9% | -1.1% | 14.0% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.94M | 14.22M | 14.47M | 23.36M | 78.44M |
| Short-term Investments | 12.09M | 37.93M | 37.75M | 74.36M | 112.97M |
| Net Receivables | 3M | 188K | 2.44M | 1.65M | 6.72M |
| Inventory | 0 | 0 | 0 | 0 | 5.49M |
| Other Current Assets | 891K | 762K | 338K | 1.48M | 1.29M |
| Total Current Assets | 56.29M | 53.1M | 55.74M | 100.85M | 204.91M |
| Property, Plant & Equipment (Net) | 21.74M | 11.07M | 7.99M | 7.98M | 13.88M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.38M | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 168K | 43K | 277K | 96K | 781K |
| Total Non-current Assets | 23.29M | 11.12M | 8.27M | 8.08M | 14.66M |
| Total Assets | 79.59M | 64.21M | 64M | 108.93M | 219.57M |
| Account Payables | 4.33M | 1.81M | 1.86M | 3.44M | 7.89M |
| Short-term Debt | 0 | 0 | 0 | 5.93M | 12.22M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 296K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.79M | 2.8M | 3.69M | 4.46M | 5.64M |
| Total Current Liabilities | 16.62M | 7.78M | 13.42M | 16.59M | 29.57M |
| Long-term Debt | 0 | 0 | 0 | 13.04M | 7.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13.04M | 23.82M | 31.35M | 32.01M | 18.9M |
| Total Non-current Liabilities | 20.6M | 29.67M | 35.75M | 48.31M | 30.78M |
| Total Liabilities | 37.22M | 37.45M | 49.18M | 64.9M | 60.35M |
| Common Stock | 1.47M | 177K | 265K | 457K | 550K |
| Retained Earnings | (655.64M) | (695.34M) | (749.52M) | (813.26M) | (742.08M) |
| Accumulated OCI | (27K) | (129K) | (66K) | 8K | 138K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 42.37M | 26.76M | 14.83M | 44.03M | 159.22M |
| Total Debt | 9.38M | 7.63M | 5.4M | 23.05M | 24.97M |
| Net Debt | (23.56M) | (6.59M) | (9.07M) | (309K) | (53.47M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.